Xintian Pharmaceutical Gets Nod to Trial Chronic Non-Bacterial Prostatitis Drug; Shares Down 3%
Xintian Pharmaceutical Gets Nod to Trial Chronic Non-Bacterial Prostatitis Drug; Shares Down 3%
新天制药获准试用慢性非细菌性前列腺炎药物；股价下跌3％
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册